LIVIVO - Search results -

Search results

Result 1 - 10 of total 53

Search options

Article ; Online: Should healthy people take calcium and vitamin D to prevent fractures? What the US Preventive Services Task Force and others say.

Dore, Robin K

2013 Volume 80, Issue 6, Page(s) 341–344

MeSH term(s)	Administration, Oral ; Advisory Committees ; Bone Density Conservation Agents/administration & dosage ; Calcium, Dietary/administration & dosage ; Fractures, Bone/prevention & control ; Humans ; United States ; Vitamin D/administration & dosage
Chemical Substances	Bone Density Conservation Agents ; Calcium, Dietary ; Vitamin D (1406-16-2)
Language	English
Publishing date	2013-06
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	639116-3
ISSN	1939-2869 ; 0891-1150
ISSN (online)	1939-2869
ISSN	0891-1150
DOI	10.3949/ccjm.80a.13050
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.212: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Clinical utility of etanercept in the treatment of arthritides in children and adolescents.

Dore, Robin K

Adolescent health, medicine and therapeutics

2014 Volume 5, Page(s) 35–48

Abstract: Juvenile idiopathic arthritis (JIA) is a group of chronic inflammatory diseases affecting approximately 300,000 children and adolescents in the United States of unknown cause. It can affect children from the age of 0 years up to the age of 16 years. The ... ...

Abstract	Juvenile idiopathic arthritis (JIA) is a group of chronic inflammatory diseases affecting approximately 300,000 children and adolescents in the United States of unknown cause. It can affect children from the age of 0 years up to the age of 16 years. The International League of Associations of Rheumatology has defined seven subsets of JIA based on several factors including the number of affected joints and the involvement of other tissues; the prognosis for each affected child also depends on multiple factors including age of onset, number of joints involved, and systemic features. As with rheumatoid arthritis in adults, the goal of therapy is remission and resolution of disease activity; however, as a cure does not seem attainable in the near future, a reasonable goal of therapy is prevention of joint damage, inhibition of inflammation, and a high level of quality of life. Even with available therapies, many children with JIA enter adulthood with persistently active disease, suboptimal function, and impaired quality of life. Methotrexate remains the standard of care for children with JIA; etanercept was approved in 2000 in the United States for the treatment of JIA resistant to methotrexate. The efficacy and safety of etanercept therapy in children with JIA is reviewed and its place in the therapeutic regimen is discussed; the available long term data is also presented. The data presented was obtained from a PubMed search as well as a review of the references presented in the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis and the 2013 Update. It is hoped that treatment with etanercept and other biologic therapies will lead to improved outcomes for children with JIA in the future.
Language	English
Publishing date	2014-03-26
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2587456-1
ISSN	1179-318X
ISSN	1179-318X
DOI	10.2147/AHMT.S38909
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis.

Dore, Robin K

Patient preference and adherence

2013 Volume 7, Page(s) 435–446

Abstract: Glucocorticoids are commonly prescribed medications to treat multiple diseases across many medical specialties. One of the most common yet largely unappreciated side effect of glucocorticoid use is increased risk of fracture. Many different therapies are ...

Abstract	Glucocorticoids are commonly prescribed medications to treat multiple diseases across many medical specialties. One of the most common yet largely unappreciated side effect of glucocorticoid use is increased risk of fracture. Many different therapies are indicated to prevent and treat this condition; many guidelines exist that suggest appropriate use of both glucocorticoids and the medications approved to prevent this common side effect of glucocorticoid therapy. Nevertheless, 30%-50% of patients on long-term glucocorticoid therapy sustain a fracture. Teriparatide, recombinant human parathyroid hormone (1-34), is a daily self-injectable therapy for 24 months approved for use in patients taking long-term glucocorticoids. Teriparatide has been shown to increase bone mineral density and reduce vertebral fracture risk in glucocorticoid-treated patients. Glucocorticoids have many adverse effects on bone that teriparatide has been shown to prevent or negate. Given the fact that preventive therapy for glucocorticoid-induced osteoporosis is often not prescribed, one wonders whether a daily self-injectable therapy for this condition would be prescribed by physicians and accepted by patients. This article reviews the epidemiology, pathophysiology, treatment, guidelines, and persistence data (when available) for patients with glucocorticoid-induced osteoporosis treated with teriparatide.
Language	English
Publishing date	2013-05-20
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2455848-5
ISSN	1177-889X
ISSN	1177-889X
DOI	10.2147/PPA.S31067
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States.

Dore, Robin K / Antonova, Jenya N / Burudpakdee, Chakkarin / Chang, Lawrence / Gorritz, Magdaliz / Genovese, Mark C

ACR open rheumatology

2021 Volume 4, Issue 6, Page(s) 473–482

Abstract: Objective: Comorbidities in rheumatoid arthritis (RA) can influence treatment selection, impact treatment persistency, and increase health care costs. This study assessed the magnitude of comorbidity burden via epidemiology (incidence and prevalence) ... ...

Abstract	Objective: Comorbidities in rheumatoid arthritis (RA) can influence treatment selection, impact treatment persistency, and increase health care costs. This study assessed the magnitude of comorbidity burden via epidemiology (incidence and prevalence) and associated costs of select comorbidities in RA patients: anemia, malignancy, venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and infections, stratified by history of disease-modifying antirheumatic drug (DMARD) exposure. Methods: From the IQVIA PharMetrics® Plus database, we selected adult patients with RA (2 or more RA diagnostic codes at least 30 days apart) at initiation of a new DMARD (DMARD-naïve), after the first conventional synthetic DMARD (csDMARD) or after the first biologic DMARD (bDMARD). We assessed pre-index prevalence (percentage) and on-treatment incidence (per 100 patient-years [P100PY]) of the aforementioned comorbidities. For patients with versus without incident conditions, we compared total all-cause health care costs as unadjusted and adjusted for baseline characteristics and health care costs. Results: Prior to initiating a new treatment, among DMARD-naïve patients (N = 28,201), csDMARD switchers (N = 7,816), or bDMARD switchers (N = 4,656), the overall prevalence ranged from 14.1% to 16.2% (anemia), from 1.3% to 5.2% (malignancy, evaluated in csDMARD and bDMARD switchers), from 1.5% to 2.1% (VTE), from 1.8% to 2.9% (MACE), and from 66.6% to 76.1% (infections). Once on index treatment, overall incidence (P100PY) among the cohorts ranged from 6.9 to 8.9 (anemia), from 2.0 to 2.3 (malignancy), from 0.7 to 0.9 (VTE), from 1.6 to 2.0 (MACE), and from 77.4 to 87.7 (infections). The incident comorbidities (except herpes zoster) were associated with increased adjusted health care costs. Conclusion: Anemia, malignancy, VTE, MACE, and infections affect patients with RA at all stages of their treatment journey and are associated with increased health care costs.
Language	English
Publishing date	2021-11-18
Publishing country	United States
Document type	Journal Article
ISSN	2578-5745
ISSN (online)	2578-5745
DOI	10.1002/acr2.11376
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The RANKL pathway and denosumab.

Dore, Robin K

Rheumatic diseases clinics of North America

2011 Volume 37, Issue 3, Page(s) 433–52, vi–vii

Abstract: Denosumab (Prolia) is a fully human monoclonal antibody directed against receptor activator of nuclear factor-κB ligand (RANKL), which interferes with the formation, activation, and survival of osteoclasts. It was approved by the Food and Drug ... ...

Abstract	Denosumab (Prolia) is a fully human monoclonal antibody directed against receptor activator of nuclear factor-κB ligand (RANKL), which interferes with the formation, activation, and survival of osteoclasts. It was approved by the Food and Drug Administration in June 2010 as a new treatment for postmenopausal osteoporosis in women who are at high risk for fracture. Given its mechanism of action, it is an antiresorptive therapy that is administered as a 60-mg subcutaneous injection every 6 months. It is the first biologic antiresorptive therapy for osteoporosis, and the first osteoporosis therapy to show efficacy and safety in patients with renal impairment.
MeSH term(s)	Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Bone Remodeling/drug effects ; Bone Remodeling/physiology ; Denosumab ; Female ; Humans ; Middle Aged ; Nuclear Export Signals/drug effects ; Nuclear Export Signals/physiology ; Osteoporosis, Postmenopausal/drug therapy ; Osteoporosis, Postmenopausal/metabolism ; RANK Ligand/antagonists & inhibitors ; RANK Ligand/metabolism
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Nuclear Export Signals ; RANK Ligand ; TNFSF11 protein, human ; Denosumab (4EQZ6YO2HI)
Language	English
Publishing date	2011-08
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	92118-x
ISSN	1558-3163 ; 0889-857X
ISSN (online)	1558-3163
ISSN	0889-857X
DOI	10.1016/j.rdc.2011.07.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 363: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Data from extension trials: denosumab and zoledronic acid.

Dore, Robin K

Current osteoporosis reports

2011 Volume 10, Issue 1, Page(s) 16–21

Abstract: Osteoporosis and fractures that occur as a result of this condition pose a huge public health problem to society and result in morbidity and mortality to individuals. Because osteoporosis is often a result of aging, many people are not aware that ... ...

Abstract	Osteoporosis and fractures that occur as a result of this condition pose a huge public health problem to society and result in morbidity and mortality to individuals. Because osteoporosis is often a result of aging, many people are not aware that therapies exist to reduce the risk of fracture. Until recently, the most common therapies used to treat osteoporosis, the oral bisphosphonates, had an inconvenient and cumbersome mode of administration. Within the last 4 years, two new parenteral antiresorptive drugs to treat osteoporosis were approved by the US Food and Drug Administration. As treatment of osteoporosis may extend for many years, the collection of long-term efficacy and safety data is warranted. This paper discusses data from the extension trials of denosumab and zoledronic acid.
MeSH term(s)	Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Bone Density/drug effects ; Bone Density Conservation Agents/administration & dosage ; Bone Density Conservation Agents/therapeutic use ; Clinical Trials as Topic ; Comorbidity ; Contraindications ; Creatinine/blood ; Denosumab ; Diphosphonates/therapeutic use ; Humans ; Imidazoles/therapeutic use ; Infusions, Intravenous ; Osteoporosis/drug therapy ; Osteoporosis/epidemiology ; Osteoporosis, Postmenopausal/drug therapy ; Osteoporotic Fractures/prevention & control ; RANK Ligand/antagonists & inhibitors ; Renal Insufficiency/epidemiology ; Treatment Outcome ; Zoledronic Acid
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Bone Density Conservation Agents ; Diphosphonates ; Imidazoles ; RANK Ligand ; Denosumab (4EQZ6YO2HI) ; Zoledronic Acid (6XC1PAD3KF) ; Creatinine (AYI8EX34EU)
Language	English
Publishing date	2011-11-16
Publishing country	United States
Document type	Journal Article
ZDB-ID	2186581-4
ISSN	1544-2241 ; 1544-1873
ISSN (online)	1544-2241
ISSN	1544-1873
DOI	10.1007/s11914-011-0082-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: How to prevent glucocorticoid-induced osteoporosis.

Dore, Robin K

Cleveland Clinic journal of medicine

2010 Volume 77, Issue 8, Page(s) 529–536

Abstract: When prescribing glucocorticoids for long-term treatment, physicians should take steps to prevent osteoporosis, a common and serious side effect of these drugs. ...

Abstract	When prescribing glucocorticoids for long-term treatment, physicians should take steps to prevent osteoporosis, a common and serious side effect of these drugs.
MeSH term(s)	Bone Density/drug effects ; Bone Density Conservation Agents/therapeutic use ; Bone and Bones/drug effects ; Calcium/therapeutic use ; Diphosphonates/therapeutic use ; Fractures, Bone/etiology ; Fractures, Bone/prevention & control ; Glucocorticoids/adverse effects ; Glucocorticoids/pharmacology ; Guideline Adherence ; Hormone Replacement Therapy ; Humans ; Immunologic Factors/therapeutic use ; Osteoporosis/chemically induced ; Osteoporosis/drug therapy ; Osteoporosis/prevention & control ; Practice Guidelines as Topic ; Vitamin D/therapeutic use
Chemical Substances	Bone Density Conservation Agents ; Diphosphonates ; Glucocorticoids ; Immunologic Factors ; Vitamin D (1406-16-2) ; Calcium (SY7Q814VUP)
Language	English
Publishing date	2010-08
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	639116-3
ISSN	1939-2869 ; 0891-1150
ISSN (online)	1939-2869
ISSN	0891-1150
DOI	10.3949/ccjm.77a.10003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.212: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The gout diagnosis.

Dore, Robin K

Cleveland Clinic journal of medicine

2008 Volume 75 Suppl 5, Page(s) S17–21

Abstract: Synovial fluid aspiration and analysis is the gold standard for making the diagnosis of gout but is not always performed when indicated in clinical practice. In clinical situations when joint aspiration simply cannot be performed, a presumptive (or ... ...

Abstract	Synovial fluid aspiration and analysis is the gold standard for making the diagnosis of gout but is not always performed when indicated in clinical practice. In clinical situations when joint aspiration simply cannot be performed, a presumptive (or clinical) diagnosis of gout may be made in consultation with published recommendations and criteria from expert societies. A thorough patient history and physical examination are critical to a presumptive diagnosis of gout, as is serum urate measurement at the time of an acute attack and at follow-up 2 weeks later.
MeSH term(s)	Biomarkers/blood ; Diagnosis, Differential ; Gout/blood ; Gout/diagnosis ; Humans ; Physical Examination/methods ; Uric Acid/blood
Chemical Substances	Biomarkers ; Uric Acid (268B43MJ25)
Language	English
Publishing date	2008-09-10
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	639116-3
ISSN	0891-1150
ISSN	0891-1150
DOI	10.3949/ccjm.75.suppl_5.s17
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.212: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Gout: what primary care physicians want to know.

Dore, Robin K

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

2008 Volume 14, Issue 5 Suppl, Page(s) S47–54

Abstract: Gout is an inflammatory arthritis that has been recognized since ancient times. It is the most common type of inflammatory arthritis in men. Despite these facts, no new advances have been made in the diagnosis and treatment of gout for over 50 years. ... ...

Abstract	Gout is an inflammatory arthritis that has been recognized since ancient times. It is the most common type of inflammatory arthritis in men. Despite these facts, no new advances have been made in the diagnosis and treatment of gout for over 50 years. Since there have been no new advances and the condition has been recognized for so many centuries, the diagnosis and treatment of gout has not elicited interest in learning more about the disease. Thus, managing gout is a challenge for the clinician caring for the gout patient. Rheumatologists should be the educators of primary care physicians (PCPs) about the diagnosis and optimal treatment of gout. A recent educational meeting was held, the Hyperuricemia and Gout Summit, in which a panel of leading rheumatologists educated PCPs about gout management through didactic presentations and breakout sessions focused on case studies. At this meeting, the PCPs discussed some of their key challenges in managing gout in their practice. This article reviews current recommendations for the diagnosis and treatment of gout, using educational examples from the Hyperuricemia and Gout Summit. It also highlights the importance of providing practical recommendations to PCPs to improve the standard of care for gout in the primary care setting.
MeSH term(s)	Anti-Inflammatory Agents/therapeutic use ; Diagnosis, Differential ; Gout/diagnosis ; Gout/drug therapy ; Gout Suppressants/therapeutic use ; Humans ; Hyperuricemia/diagnosis ; Hyperuricemia/drug therapy ; Physicians, Family/education ; Rheumatology/education ; Rheumatology/trends
Chemical Substances	Anti-Inflammatory Agents ; Gout Suppressants
Language	English
Publishing date	2008-10
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1283266-2
ISSN	1536-7355 ; 1076-1608
ISSN (online)	1536-7355
ISSN	1076-1608
DOI	10.1097/RHU.0b013e3181896c35
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4815: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Videos using different message strategies to promote the interruption of sedentary behavior in university students during online lectures - A pilot study.

Doré, Anastasia / Kalo, Kristin / Schwab, Lisa / Reichel, Jennifer L / Eisenbarth, Laura / Strepp, Tilmann / Jacob, Robin / Enders, Kira / Letzel, Stephan / Simon, Perikles / Dietz, Pavel / Kubiak, Thomas / Heller, Sebastian

Frontiers in public health

2023 Volume 11, Page(s) 1108154

Abstract: Background: Sedentary behavior (SB) is highly prevalent among university students and has increased during COVID-19 pandemic. As SB is associated with negative health outcomes, appropriate prevention measures in the university setting are needed.: ... ...

Abstract	Background: Sedentary behavior (SB) is highly prevalent among university students and has increased during COVID-19 pandemic. As SB is associated with negative health outcomes, appropriate prevention measures in the university setting are needed. Objective: This pilot study aimed at investigating the effects of videos using different message strategies to interrupt SB in the collective of university students during online lectures. Methods: During online lectures, university students ( Results: Approximately half of the students interrupted sedentary behavior during watching the videos and students of the older age group (cut-off: median = 22 years) interrupted SB significantly more often ( Conclusion: Considering the increased digitalization in general and restrictions due to COVID-19 pandemic, videos seem to be a useful tool to interrupt SB among university students during online lectures. Narrative formats could facilitate the intention to reduce SB, which in turn could have a positive impact on the interruption of SB. However, further research on effective communication and message strategies is needed.
MeSH term(s)	Humans ; Aged ; Universities ; Pilot Projects ; Sedentary Behavior ; Pandemics ; COVID-19/epidemiology ; Students
Language	English
Publishing date	2023-07-27
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2711781-9
ISSN	2296-2565 ; 2296-2565
ISSN (online)	2296-2565
ISSN	2296-2565
DOI	10.3389/fpubh.2023.1108154
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito